SCHEMBL485790

SCHEMBL485790

O=C(NC1CCC1)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.47
CNR2 P34972 6/20 0.45
CNR1 P21554 5/20 0.45
DRD4 P21917 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP3A5 P20815 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SGMS2 Q8NHU3 1/20 0.42
HCRTR1 O43613 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 1/20 0.39
NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485579 0.98 CXCR2 (0.47) CXCR2CNR2CNR1DRD4CYP3A4
SCHEMBL485784 0.87 CXCR2 (0.44) CXCR2CNR2CNR1CYP3A4CYP3A5
SCHEMBL485699 0.86 CXCR2 (0.62) CXCR2CNR2CNR1DRD4ALDH1A1
SCHEMBL485840 0.84 MRGPRX4 (0.47) CNR2CNR1CYP3A4CYP3A5ALDH1A1
SCHEMBL485511 0.84 CXCR2 (0.62) CXCR2CNR2CNR1DRD4ALDH1A1
Formic Acid SCHEMBL27713007 0.83 CYP3A4 (0.47) CNR2CNR1DRD4CYP3A4CYP3A5
Formic Acid SCHEMBL27713047 0.83 CXCR2 (0.58) CXCR2CNR2CNR1DRD4ALDH1A1
SCHEMBL1598461 0.83 CXCR2 (0.49) CXCR2ALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL485455 0.83 CXCR2 (0.49) CXCR2CNR2CNR1DRD4ALDH1A1
SCHEMBL485894 0.82 CXCR2 (0.48) CXCR2CNR2CNR1DRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP claimed